becton dickinson co nyse qqq
bd continu deliv bard integr target
updat forecast estim feb
conduct analyst
govern code ethics/cod conduct
polici secur trade polici
equival invest research
interest visit
primari analyst cover compani
stock
research feb
estim feb
price data feb
rate updat feb
currenc amount express
busi strategi outlook
methodolog valu compani
busi strategi outlook
becton dickinson certainli keen abandon predict
compani monik surpris investor commun three
year ago first major acquisit oper histori
bd doubl carefus deal size purchas
 bard big fan bard believ addit
higher-growth busi along reinvigor perform
bd legaci busi push compani
organ revenu growth improv may seem
particularli impress nonetheless sizeabl jump
compani compet product area histor
experienc growth broader medic sector bd
product pipelin potenti expand
overal size market posit compani full-suit
product solut vendor
essenti natur bd medic product given
compani ampl cash flow reinvest bd made
consciou effort deploy capit bolster offer
area diabet inject bioscienc compani
also built massiv presenc emerg market
distribut manufactur network unparallel med
tech world return intern invest becom
evid form improv organ growth compani
increasingli turn acquisit
acquisit carefus first sign bd depart
century-old strategi bolt-on acquisit
bard deal move compani even away comfort
zone bard bring challeng oper area
competit deep-pocket research develop
commit requir carefus product suit provid
mani complementari opportun bd
product maxim bard potenti challeng
said believ bd allow bard autonomi
particularli pertain spend area pad
give us confid compani postmerg goal
revenu growth synergi line
valuat summari forecast
financi summari forecast
historical/forecast data sourc morningstar estim may reflect adjust
becton dickinson world largest manufactur distributor
medic surgic product needl syring sharps-dispos
unit compani also manufactur diagnost instrument reagent
well flow cytometri cell-imag system revenu
account compani busi carefus bd
enter medic system infus pump ventil
well procedur solut busi bard deal give compani
presenc urolog vascular oncolog
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
rais fair valu estim per share
mainli due cash flow realiz sinc last year
well strong perform
bard brought lead product portfolio strong
engin onu bd maintain posit
signific integr risk play although
give bd benefit doubt model growth
bard segment next five year along
legaci busi recent increas growth rate
across board larg unchang sever
driver behind recent revis growth forecast first
core medic busi see effect
signific invest firm pipelin
strongest long time origin bd
product suit carefus portfolio medic
dispens pump expand firm
launch innov product across spectrum firm
also expand presenc informat
histor
interconnect import pillar bd new strategi
aim control larger portion care
continuum diseas manag particularli area like
diabet bd alway strong attract
opportun develop world emerg
also recent rais forecast bd lifesci
diagnost segment still face challeng
tripath busi compani lack scale
product breadth larger player made invest
higher-growth area mainli molecular diagnost
autom expand assay portfolio bd max
schedul launch high-volum molecular system
next year make greater inroad
bd emphasi profit allow expand
oper margin despit on-going price pressur raw
materi inflat although incorpor sizeabl
margin boost current level forecast -- less
basi point per year believ compani
abl extract oper synergi carefus
histor rang bd plausibl scenario outcom
fairli tight due predict natur
medic divis cash flow key driver bull
bear scenario firm revenu growth abil
success integr carefus particular bard
rang revenu growth outcom still fairli
compound annual five-year growth
bull bear scenario respect howev
see volatil futur cash flow given
uncertainti surround bd abil integr
deal unpreced size best-cas
scenario fair valu estim bd per share
foundat bd moat manufactur scale
basic surgic product segment account
half compani busi compani
largest manufactur needles/syring competit
match compani scale make compet price
difficult said compani entir
price-sett busi commoditylik
price increas primarili achiev product mix
decreas matur line off-set higher price new
product introduct bd diagnost busi squar
narrow-moat bucket robust instal base
respons steadi recur revenu provid
switch cost defenc new entrant howev
compani assay lack signific differenti
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
particular brand devic rare switch thank
retrain cost well product process familiar
compani like carefus larg instal base
devic enjoy low custom turnov stream
recur revenu associ dispos long
oper life devic
bard dug narrow moat divers portfolio
differenti product patent protect
innov addit manag done credibl
job ad new product includ new technolog
requir market develop expand bard wide
rang product primarili variou acquisit
firm well posit provid hospit custom
group purchas organ one-stop shop
prospect bundl deal compani abil
make meaning innov key product
foley cathet allow firm stave price
pressur maintain presenc equip shelf
bard solidifi narrow moat relationship
practition vascular surgic urolog
oncolog area tie bard seek cultiv
physician prefer product
compani busi less presenc weaker
diagnost bioscienc area face mani
challeng warrant wide econom moat
carefus busi oligopoli matur domest
market certain would abl deploy
current tactic emerg market bd attempt
expand presenc higher-price-point product
suscept capital-spend fluctuat
develop world less pronounc emerg
market particularli carefus brand
cachet initi barrier entri rather low
bard critic variabl bd abil
success navig challeng integr bard
innov aggress natur bd conserv
reliant continu innov off-set price pressur
age portfolio bioscienc segment
would also like receiv narrow moat rate firm
hold lead posit flow cytomet invest
heavili expand presenc broader cell-therapi
market still lack breadth capabl
carefus narrow moat stem high product
switch cost substanti barrier entri deriv
larg portion revenu product
market leader intraven infus pump
respir ventil
infection-control product carefus maintain
number-on market posit mani product
categori especi infus pump medication-dispens
equip estim hold global
share respect infus market particular
rel oligopoli carefus baxter hospira
braun control market new smaller
entrant hard time contend
establish player scale breadth product offer
product familiar hospit familiar
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
structur bd compet area
histor virtual zero presenc certain
stage moat benefit presenc
bard portfolio product
view bd moat trend stabl post-acquisit
compani manufactur infrastructur surgic
busi sizeabl hurdl potenti new entrant
competit fairli intens among exist industri
particip primarili commoditis natur
mani firm product compani inabl
consist rais price even line inflat
testament industri tough competit dynam
growth compani manufactur infrastructur
particularli outsid strengthen scale
advantag view overal competit advantag
stabl
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
obard bring lead pad franchis
odevelop market fulli convert safeti
mandat convert place eu bd
abil expand mature-market safeti
obd max enjoy strong adopt
test menu grow platform continu
ogrowth compani hospit consum
capit equip product line like remain
weak healthcar provid remain cautiou
cash deploy
challeng keep key leader crucial
obd acquisit strategi new risk compani
avoid transform deal
long histori
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
equival begin period
total avail debt servic
oblig commit
total oblig commit
adjust free
gener
gener revolv adjust
commit
bd leverag financ bard acquisit given
ampl stabl cash flow model bd success
reduc debt load commenc buy-back program
five year financ billion came form
convert prefer stock mandatori convers
bd surgic product commoditylik make
differenti virtual non-existent forc firm
compet price field diagnost bioscienc
bd number rival abbott roch
possess greater market reach larger research
develop budget academ govern
spend environ unit state
europ may remain constrain long period
neg affect demand firm research
instrument bard acquisit challeng
integr much valu deal stem sale
oper synergi well compani abil
retain key bard personnel innov cultur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
ceo/chairman board/
repres date owner name posit common share held report holder issuer
fidel manag research compani
america corpor
new york mellon corp
share
fund
share
fund
compani execut among best industri
term capit alloc view assign bd
exemplari stewardship grade year firm
focus return invest capit wise capit
deploy limit growth acquisit
run major oper mishap
compani success record speak highli
longev bd strong return capit particularli
remark given half firm busi belong
manag appear understand take
basic medic devic
invest go steadili expans
manufactur footprint solidifi scale advantag
competit compani manag expand
presenc basic medic devic maintain robust
return competitor often exit arena
histor bd resist temptat sizeabl
acquisit instead focus fill small product gap
rather market share grab carefus bard
deal departur histor strategi
manag team far deliv promis
particularli impress abil extract
cost synergi low-hang fruit consid
carefus rel bloat cost structur also
manag step far increas growth
core carefus busi histor level
requir bolster exist portfolio
meaning invest leverag
infrastructur deliv carefus product geographi
previous lack capac new long-term
growth target incorpor elev perform
integr bard even challeng consid
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
bard portfolio product requir higher capit
intens cautious optimist bd retain
bard key personnel leav cultur intact
result bard remain top-tier player devic
number key bard execut sever segment
post-acquisit bd led ex-bard manag
critic maintain innov cultur
allow bard becom one best-run medic devic
come govern practic compani
shareholder-friendli polici place consid
gener success align corpor perform
execut pay top manag also requir
receiv portion total pay compani stock
disclosur detail compani
histor avoid pollut financi statement
non-gaap adjust though polici chang
larg amortis expens hit incom
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
becton dickinson report line first-quart result
revenu currency-neutr basi earn
mainli result favor tax time
plan rais fair valu estim account cash
flow realiz sinc last updat share fairli
valu current level narrow-moat rate
perform medic segment mix
medic manag solut pharmaceut
busi strength off-set fairli weak diabet
quarter infus led growth busi
capit spend environ remain rather
attract pyxi continu gain share
dispens weak diabet md
structur rather timing/comp relat life scienc
segment neg affect strong flu
anticip
highlight includ in-lin drug-coat balloon sale
anticip effect paclitaxel studi releas
decemb fulli digest market sever
trial report suspens recruit effort dcb
fda came support dcb pad
suspect next quarter give us better vantag point
impact studi lutonix franchis
geographi bit surpris rel weak
perform emerg market
organ quarter despit china still grow
strongli compani point revenu time
note strong order backlog bd re-affirmed full-year
guidanc impli bounceback emerg market
medic raw materi resin particular provid
headwind earn line bard synergi expect
intact
life scienc diagnost industri offer attract
growth moat wari valuat
think plenti like life scienc
sever competit advantag lead econom
moat industri tend predict
attract growth outlook especi area
bioprocess analyt instrument genom
addit somewhat insul broader
macroeconom cycl nearli everi compani life
scienc diagnost manufactur coverag also earn
econom moat thank intang often pair
high switch cost valuat alreadi reflect
optim howev multipl across industri
look expens view current think water
agil becton dickinson reflect best
valu trade close territori view mettler
biomerieux significantli overvalu
moat common life scienc tool thank intang
switch cost gener award moat life
scienc diagnost firm record consist
innov larg instal base equip
dedic pull consum
chromatographi mass spectrometri market led
water agil creat one wide-moat
segment benefit low disrupt risk high
barrier entri comfort oligopoli razor-and-
blade busi model high custom switch cost
nich ga
outlook life scienc diagnost market
remain stabl attract pocket growth
estim market exce roughli billion grow
nearli annual depend market
segment popul growth increas drug research
volum workflow improv rise manufactur
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
compani take cautiou approach macro
environ tariff expect impact
busi top line raw materi resin
particular provid headwind earn line
nonetheless guidanc far forecast
make materi chang model bd
quantifi bard revenu synergi million
higher compani got carefus
larg anticip investor
qualiti standard emerg field genet research
test key industri growth driver
complet overview life scienc moat analysi
pleas see report life scienc diagnost industri
offer attract growth econom moat wari
valuat discuss growth outlook
econom moat life scienc industri
guidanc affect tariff raw materi
result revenu currency-neutr basi
ahead expect compani guidanc
slightli weaker anticip howev bd
attribut larg macro headwind includ tariff
like slightli rais fair valu estim
account cash flow realiz sinc last updat
share appear fairli valu current level narrow
moat rate unchang
area medic segment deliv good result
medic manag solut
busi grew impress quarter
albeit aid somewhat order time pump side
bd target launch next updat pyxi es platform
support reacceler growth
dispens medic deliveri solut deliv
result target support new normal
growth segment roughli basi
point higher previou forecast
segment larg line estim
geographi market deliv best quarter
year emerg market organ
quarter china still grow strongli
bd guidanc somewhat conserv
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
financi summari forecast
fiscal year end septemb
earn interest tax
return asset
return equiti
valuat summari forecast
equiti
pre-tax debt
weight averag capit
addit estim scenario avail download http //select morningstar com
equival
data tabl repres base-cas forecast compani report
currenc begin current year fair valu estim may differ
equiti valu per share shown due time valu money adjust case
probability-weight scenario analysi perform
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
page
becton dickinson co nyse qqq
fiscal year end septemb
good sold
depreci amort report separ
impair charg report separ
morningstar right reserv unless otherwis provid separ agreement may use report countri origin distributor base inform data analys opinion present herein constitut
invest advic provid sole inform purpos therefor offer buy sell secur warrant correct complet accur opinion express date written subject chang without
notic except otherwis requir law shall respons trade decis damag loss result relat inform data analys opinion use inform contain herein
proprietari properti may reproduc whole part use manner without prior written consent invest research produc issu subsidiari inc includ limit
morningstar research servic llc regist govern secur exchang commiss order reprint call licens research call pleas see import disclosur end report
